IGC Pharma Inc
Veridion Score
Composite trend over time
Why is IGC moving today?
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
Real vendor fields plus Veridion-computed history. Missing fields stay blank.
Warehouse intelligence for IGC.
IGC insider activity
IGC Pharma Inc
2 insiders bought in the last 90 days
Net buying: $120K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-06 | 2026-04-01 | GRIMALDI CLAUDIA | Insider | buy | $0.26 | 138,462 | 1,372,714 | $36K | SEC Form 4 |
| 2026-04-06 | 2026-04-01 | Mukunda Ram | Insider | buy | $0.26 | 323,077 | 4,649,088 | $84K | SEC Form 4 |
IGC contract awards, year to date.
Public federal awards linked to this ticker.
IGC lobbying filings, year to date.
Registered lobbying filings matched to IGC Pharma Inc.